Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IKT Inhibikase Therapeutics	$1.66 -2.4%	$1.99	$1.12 ▼ $4.20	$123.41M	0.94	242,650 shs	278,054 shs
SAGE Sage Therapeutics	$9.30 +1.9%	$7.20	$4.62 ▼ $13.47	$582.37M	0.18	1.27 million shs	2.60 million shs
SANA Sana Biotechnology	$2.61 -5.4%	$2.07	$1.26 ▼ $7.40	$588.49M	1.78	3.61 million shs	11.69 million shs
VECT VectivBio	$16.85	$16.85	$4.25 ▼ $16.98	N/A	N/A	N/A	N/A

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IKT Inhibikase Therapeutics	0.00%	-10.75%	-9.78%	-29.96%	+11.41%
SAGE Sage Therapeutics	0.00%	+38.81%	+40.70%	+14.81%	-13.49%
SANA Sana Biotechnology	0.00%	+0.77%	+30.50%	+12.99%	-54.05%
VECT VectivBio	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IKT Inhibikase Therapeutics	1.4756 of 5 stars	3.3	1.0	0.0	0.0	0.0	0.0	1.3
SAGE Sage Therapeutics	2.9462 of 5 stars	2.0	1.0	0.0	4.0	2.9	1.7	0.6
SANA Sana Biotechnology	2.3495 of 5 stars	3.4	0.0	0.0	0.0	2.8	3.3	0.6
VECT VectivBio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IKT Inhibikase Therapeutics	2.50	Moderate Buy	$6.50	291.57% Upside
SAGE Sage Therapeutics	2.00	Hold	$8.93	-3.94% Downside
SANA Sana Biotechnology	2.86	Moderate Buy	$10.80	313.79% Upside
VECT VectivBio	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest IKT, VECT, SANA, and SAGE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	SAGE Sage Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$7.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$9.00 ➝ $8.50
6/17/2025	SAGE Sage Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Hold ➝ Hold	$8.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$12.00
6/17/2025	SAGE Sage Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$8.00 ➝ $8.50
6/16/2025	SAGE Sage Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
4/25/2025	SAGE Sage Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
4/24/2025	SANA Sana Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00
3/28/2025	IKT Inhibikase Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral

(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IKT Inhibikase Therapeutics	$260K	474.65	N/A	N/A	$1.78 per share	0.93
SAGE Sage Therapeutics	$41.24M	14.12	N/A	N/A	$7.60 per share	1.22
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$1.12 per share	N/A
VECT VectivBio	$27.34M	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IKT Inhibikase Therapeutics	-$19.03M	-$2.67	N/A	N/A	N/A	N/A	-350.63%	-201.82%	N/A
SAGE Sage Therapeutics	-$400.67M	-$5.80	N/A	N/A	N/A	-747.63%	-68.99%	-60.67%	7/30/2025 (Estimated)
SANA Sana Biotechnology	-$266.76M	-$0.88	N/A	N/A	N/A	N/A	-86.58%	-44.49%	8/6/2025 (Estimated)
VECT VectivBio	-$93.74M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest IKT, VECT, SANA, and SAGE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/8/2025	Q1 2025	SANA Sana Biotechnology	-$0.22	-$0.20	+$0.02	-$0.21	N/A	N/A
4/29/2025	Q1 2025	SAGE Sage Therapeutics	-$0.99	-$1.01	-$0.02	-$1.01	$14.12 million	$14.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	N/A
SAGE Sage Therapeutics	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A
VECT VectivBio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IKT Inhibikase Therapeutics	N/A	0.85	0.85
SAGE Sage Therapeutics	N/A	9.13	9.13
SANA Sana Biotechnology	N/A	3.40	3.40
VECT VectivBio	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IKT Inhibikase Therapeutics	3.81%
SAGE Sage Therapeutics	99.22%
SANA Sana Biotechnology	88.23%
VECT VectivBio	N/A

Insider Ownership

Company	Insider Ownership
IKT Inhibikase Therapeutics	7.30%
SAGE Sage Therapeutics	5.50%
SANA Sana Biotechnology	31.10%
VECT VectivBio	9.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IKT Inhibikase Therapeutics	6	74.34 million	66.18 million	Not Optionable
SAGE Sage Therapeutics	690	62.62 million	59.18 million	Optionable
SANA Sana Biotechnology	380	225.48 million	155.35 million	Optionable
VECT VectivBio	30	N/A	N/A	No Data

IKT, VECT, SANA, and SAGE Headlines

Recent News About These Companies

Ironwood’s shares sink as FDA demands new trial for lead drug

April 15, 2025 | msn.com

A brain biotech launches with Roche’s spare parts

February 13, 2025 | biopharmadive.com

Aravax Continues International Expansion with Appointment of Aled Williams as Chief Business Officer

January 21, 2025 | markets.businessinsider.com

CDR-Life Appoints Sarah Holland, PhD, as Chief Business Officer

December 5, 2024 | finance.yahoo.com

Recent advances in clinical practice: mastering the challenge—managing IBS symptoms in IBD

November 12, 2024 | gut.bmj.com

Graft versus Host Disease Market to Increase at a CAGR of 9.9% During the Study Period (2020–2034) | DelveInsight

September 23, 2024 | finance.yahoo.com

Etherio Group: 2024 CMI 25

September 21, 2024 | meetingsnet.com

Compare with VectivBio Holding AG (VECT)

May 29, 2024 | msn.com

enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

May 15, 2024 | finance.yahoo.com

Vicore Pharma Holding: Vicore Expands and Strengthens its Board of Directors

May 14, 2024 | finanznachrichten.de

Vicore Expands and Strengthens its Board of Directors

May 14, 2024 | finance.yahoo.com

Short Bowel Syndrome Market by 2032: Forecast Report Estimates Significant Growth

April 5, 2024 | uk.finance.yahoo.com

FDA approves DMD treatment from Italfarmaco

March 31, 2024 | cen.acs.org

Pipeline moves: Approval prospects for SBS candidate rise after Phase III trial meets endpoints

March 18, 2024 | msn.com

Ironwood Nabs Phase III Win, Still Sees Stock Nosedive

March 1, 2024 | biospace.com

Ironwood felled by mixed data in short bowel syndrome trial

March 1, 2024 | pharmaphorum.com

UPDATE 3-Ironwood's bowel disease drug meets main goal of late-stage study

March 1, 2024 | msn.com

Ironwood's bowel disease treatment meets main goal in late-stage trial

February 29, 2024 | reuters.com

Why Is Gastrointestinal Healthcare Focused Ironwood Pharmaceuticals Stock Sinking On Thursday?

February 29, 2024 | benzinga.com

Only two sleeps left until February 31!

February 29, 2024 | ft.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IKT, VECT, SANA, and SAGE Company Descriptions

Inhibikase Therapeutics NYSE:IKT

$1.66 -0.04 (-2.35%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$1.67 +0.01 (+0.60%)

As of 06/20/2025 05:23 PM Eastern

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

Sage Therapeutics NASDAQ:SAGE

$9.30 +0.17 (+1.86%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$9.17 -0.13 (-1.40%)

As of 06/20/2025 07:57 PM Eastern

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Sana Biotechnology NASDAQ:SANA

$2.61 -0.15 (-5.43%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$2.68 +0.06 (+2.49%)

As of 06/20/2025 07:59 PM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

VectivBio NASDAQ:VECT

$16.85 0.00 (0.00%)

As of 06/20/2025

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time